

U.S. Court Grants Judgment for Boston Scientific in Cases brought by Medtronic

(January 6, 2005)-- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. District Court in Delaware has granted summary judgment of non-infringement in favor of Boston Scientific, finding that Boston Scientific's Express™ stent does not infringe four Medtronic patents. The Express stent is the platform for Boston Scientific's market-leading TAXUS™ Express²™ paclitaxel-eluting coronary stent system. In a separate case brought by Medtronic involving the NIR® stent sold by Boston Scientific, the court also granted summary judgment of non-infringement in favor of Boston Scientific, finding that the NIR stent does not infringe the Medtronic patents.

"We are pleased with the court's decision," said Boston Scientific spokesman Paul Donovan. "It allows doctors to continue to improve patients

<https://news.bostonscientific.com/news-releases?item=58732>